$234.330
+4.452 (+1.90%)At close
ASND News
ASND Events
Ascendis Pharma Recommended for EU Marketing Authorization of TransCon CNP
Ascendis Pharma announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted an opinion recommending marketing authorization for once-weekly TransCon CNP in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission, or EC, decision on Ascendis Pharma's Marketing Authorization Application, or MAA, is expected during Q4.
Ascendis Pharma Shares Drop 12.8% to $231.00
Ascendis Pharma is down -12.8%, or -$33.92 to $231.00.
Ascendis Pharma Shares Drop 12.1% to $232.78
Ascendis Pharma is down -12.1%, or -$32.14 to $232.78.
Ascendis Pharma Authorizes $400M Share Buyback
Ascendis Pharma announced that its Board of Directors has authorized the company to repurchase up to $400M of the company's ordinary shares.
Ascendis Pharma Regains Exclusive Rights to TransCon Technology
Ascendis Pharma (ASND) announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S (NVS) announced in November 2024. Under the terms of the agreement, following termination all licenses granted to Novo Nordisk in metabolic and cardiovascular diseases, including for once-monthly TransCon Semaglutide, will revert to Ascendis, and neither party has any continuing financial obligations to the other. Upon effective termination and reversion of rights, Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications, where it believes it can establish best-in-class therapies. These new programs include advancing once-monthly TransCon Semaglutide, an investigational long-acting prodrug of the GLP-1 receptor agonist semaglutide, as a potential treatment for obesity and type 2 diabetes.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.